Pharmacodynamic assessment of prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial

Prasugrel, a novel P2Y(12) receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. We investigated the dose–response antiplatelet effects of prasugrel compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Takenori, Shirai, Toshiaki, Yoshiba, Satoshi, Abe, Kenji, Ikeda, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954144/
https://www.ncbi.nlm.nih.gov/pubmed/31643039
http://dx.doi.org/10.1007/s11239-019-01926-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954144/
https://www.ncbi.nlm.nih.gov/pubmed/31643039
http://dx.doi.org/10.1007/s11239-019-01926-6

Ejemplares similares